131 related articles for article (PubMed ID: 38853909)
1.
Desai D; Song T; Singh RR; Baby A; McNamara J; Green L; Nabavizadeh P; Ericksen M; Bazrafshan S; Natesan S; Sadayappan S
bioRxiv; 2024 May; ():. PubMed ID: 38853909
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the Contribution of a Thermodynamic and Mechanical Destabilization of Myosin-Binding Protein C Domain C2 to the Pathomechanism of Hypertrophic Cardiomyopathy-Causing Double Mutation
Schwäbe FV; Peter EK; Taft MH; Manstein DJ
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769381
[TBL] [Abstract][Full Text] [Related]
3. Slower Calcium Handling Balances Faster Cross-Bridge Cycling in Human
Pioner JM; Vitale G; Steczina S; Langione M; Margara F; Santini L; Giardini F; Lazzeri E; Piroddi N; Scellini B; Palandri C; Schuldt M; Spinelli V; Girolami F; Mazzarotto F; van der Velden J; Cerbai E; Tesi C; Olivotto I; Bueno-Orovio A; Sacconi L; Coppini R; Ferrantini C; Regnier M; Poggesi C
Circ Res; 2023 Mar; 132(5):628-644. PubMed ID: 36744470
[TBL] [Abstract][Full Text] [Related]
4. Association of Cardiomyopathy With MYBPC3 D389V and MYBPC3Δ25bpIntronic Deletion in South Asian Descendants.
Viswanathan SK; Puckelwartz MJ; Mehta A; Ramachandra CJA; Jagadeesan A; Fritsche-Danielson R; Bhat RV; Wong P; Kandoi S; Schwanekamp JA; Kuffel G; Pesce LL; Zilliox MJ; Durai UNB; Verma RS; Molokie RE; Suresh DP; Khoury PR; Thomas A; Sanagala T; Tang HC; Becker RC; Knöll R; Shim W; McNally EM; Sadayappan S
JAMA Cardiol; 2018 Jun; 3(6):481-488. PubMed ID: 29641836
[TBL] [Abstract][Full Text] [Related]
5. A hypertrophic cardiomyopathy-associated MYBPC3 mutation common in populations of South Asian descent causes contractile dysfunction.
Kuster DW; Govindan S; Springer TI; Martin JL; Finley NL; Sadayappan S
J Biol Chem; 2015 Feb; 290(9):5855-67. PubMed ID: 25583989
[TBL] [Abstract][Full Text] [Related]
6. MYBPC3-c.772G>A mutation results in haploinsufficiency and altered myosin cycling kinetics in a patient induced stem cell derived cardiomyocyte model of hypertrophic cardiomyopathy.
Steczina S; Mohran S; Bailey LRJ; McMillen TS; Kooiker KB; Wood NB; Davis J; Previs MJ; Olivotto I; Pioner JM; Geeves MA; Poggesi C; Regnier M
J Mol Cell Cardiol; 2024 Jun; 191():27-39. PubMed ID: 38648963
[TBL] [Abstract][Full Text] [Related]
7. The mechanics of the heart: zooming in on hypertrophic cardiomyopathy and cMyBP-C.
Suay-Corredera C; Alegre-Cebollada J
FEBS Lett; 2022 Mar; 596(6):703-746. PubMed ID: 35224729
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of MYBPC3 trans-Splicing and Gene Replacement as Therapeutic Options in Human iPSC-Derived Cardiomyocytes.
Prondzynski M; Krämer E; Laufer SD; Shibamiya A; Pless O; Flenner F; Müller OJ; Münch J; Redwood C; Hansen A; Patten M; Eschenhagen T; Mearini G; Carrier L
Mol Ther Nucleic Acids; 2017 Jun; 7():475-486. PubMed ID: 28624223
[TBL] [Abstract][Full Text] [Related]
9. Altered C10 domain in cardiac myosin binding protein-C results in hypertrophic cardiomyopathy.
Kuster DWD; Lynch TL; Barefield DY; Sivaguru M; Kuffel G; Zilliox MJ; Lee KH; Craig R; Namakkal-Soorappan R; Sadayappan S
Cardiovasc Res; 2019 Dec; 115(14):1986-1997. PubMed ID: 31050699
[TBL] [Abstract][Full Text] [Related]
10. A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay.
Seeger T; Shrestha R; Lam CK; Chen C; McKeithan WL; Lau E; Wnorowski A; McMullen G; Greenhaw M; Lee J; Oikonomopoulos A; Lee S; Yang H; Mercola M; Wheeler M; Ashley EA; Yang F; Karakikes I; Wu JC
Circulation; 2019 Feb; 139(6):799-811. PubMed ID: 30586709
[TBL] [Abstract][Full Text] [Related]
11. Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes.
Ramachandra CJA; Kp MMJ; Chua J; Hernandez-Resendiz S; Liehn EA; Knöll R; Gan LM; Michaëlsson E; Jonsson MKB; Ryden-Markinhuhta K; Bhat RV; Fritsche-Danielson R; Lin YH; Sadayappan S; Tang HC; Wong P; Shim W; Hausenloy DJ
Cardiovasc Res; 2022 Jan; 118(2):517-530. PubMed ID: 33705529
[TBL] [Abstract][Full Text] [Related]
12. Hypertrophic cardiomyopathy-linked variants of cardiac myosin-binding protein C3 display altered molecular properties and actin interaction.
Da'as SI; Fakhro K; Thanassoulas A; Krishnamoorthy N; Saleh A; Calver BL; Safieh-Garabedian B; Toft E; Nounesis G; Lai FA; Nomikos M
Biochem J; 2018 Dec; 475(24):3933-3948. PubMed ID: 30446606
[TBL] [Abstract][Full Text] [Related]
13. SarcTrack.
Toepfer CN; Sharma A; Cicconet M; Garfinkel AC; Mücke M; Neyazi M; Willcox JAL; Agarwal R; Schmid M; Rao J; Ewoldt J; Pourquié O; Chopra A; Chen CS; Seidman JG; Seidman CE
Circ Res; 2019 Apr; 124(8):1172-1183. PubMed ID: 30700234
[TBL] [Abstract][Full Text] [Related]
14. Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice.
Stöhr A; Friedrich FW; Flenner F; Geertz B; Eder A; Schaaf S; Hirt MN; Uebeler J; Schlossarek S; Carrier L; Hansen A; Eschenhagen T
J Mol Cell Cardiol; 2013 Oct; 63():189-98. PubMed ID: 23896226
[TBL] [Abstract][Full Text] [Related]
15. Diltiazem prevents stress-induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3-knock-in mice.
Flenner F; Geertz B; Reischmann-Düsener S; Weinberger F; Eschenhagen T; Carrier L; Friedrich FW
J Physiol; 2017 Jun; 595(12):3987-3999. PubMed ID: 28090637
[TBL] [Abstract][Full Text] [Related]
16. Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function.
van Dijk SJ; Paalberends ER; Najafi A; Michels M; Sadayappan S; Carrier L; Boontje NM; Kuster DW; van Slegtenhorst M; Dooijes D; dos Remedios C; ten Cate FJ; Stienen GJ; van der Velden J
Circ Heart Fail; 2012 Jan; 5(1):36-46. PubMed ID: 22178992
[TBL] [Abstract][Full Text] [Related]
17. Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics.
Bhagwan JR; Mosqueira D; Chairez-Cantu K; Mannhardt I; Bodbin SE; Bakar M; Smith JGW; Denning C
J Mol Cell Cardiol; 2020 Aug; 145():43-53. PubMed ID: 32531470
[TBL] [Abstract][Full Text] [Related]
18. Hypertrophic cardiomyopathy dysfunction mimicked in human engineered heart tissue and improved by sodium-glucose cotransporter 2 inhibitors.
Wijnker PJM; Dinani R; van der Laan NC; Algül S; Knollmann BC; Verkerk AO; Remme CA; Zuurbier CJ; Kuster DWD; van der Velden J
Cardiovasc Res; 2024 Mar; 120(3):301-317. PubMed ID: 38240646
[TBL] [Abstract][Full Text] [Related]
19. Deficient cMyBP-C protein expression during cardiomyocyte differentiation underlies human hypertrophic cardiomyopathy cellular phenotypes in disease specific human ES cell derived cardiomyocytes.
Monteiro da Rocha A; Guerrero-Serna G; Helms A; Luzod C; Mironov S; Russell M; Jalife J; Day SM; Smith GD; Herron TJ
J Mol Cell Cardiol; 2016 Oct; 99():197-206. PubMed ID: 27620334
[TBL] [Abstract][Full Text] [Related]
20. Haploinsufficiency of MYBPC3 exacerbates the development of hypertrophic cardiomyopathy in heterozygous mice.
Barefield D; Kumar M; Gorham J; Seidman JG; Seidman CE; de Tombe PP; Sadayappan S
J Mol Cell Cardiol; 2015 Feb; 79():234-43. PubMed ID: 25463273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
